Clinical trial · Observational
SAlt Diet and Various Biomarkers Effects on Blood Pressure and Proteinuria During Inhibition of VEGF)
NCT03842917CI-TRIAL-00062039SAVEcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Bevacizumab is an anti-angiogenic treatment used to treat various solid cancers. Previous studies have shown that this treatment may have adverse effects like hypertension and proteinuria. This is an exploratory study aiming to better understand the relationship between various biomarkers and blood pressure changes and proteinuria measured for 4 to 6 weeks after the first infusion of anti-VEGF therapy with bevacizumab.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Patient Starting Bevacizumab | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Biological samples | Other | — | UNRESOLVED |
| Blood pressure measurement | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patient starting bevacizumab treatment for cancer
- description
- Taken biological samples (urine and blood) and blood pressure measurement on patients starting bevacizumab treatment for cancer
- interventionNames
- Other: Biological samples
- Other: Blood pressure measurement
Primary outcomes (1)
- measure
- Home blood pressure measurement
- timeFrame
- before the initiation of bevacizumab and before each bevacizumab infusion, up to 10 weeks
- description
- Home blood pressure (systolic, diastolic) before each bevacizumab infusion, as the mean of 3 measures in the morning and 3 measures in the evening, over 3 days
Secondary outcomes (2)
- measure
- in-hospital blood pressure measurement
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patient * With a solid cancer for which a treatment with bevacizumab (Avastin®) is indicated in accordance with its marketing authorization Exclusion Criteria: * Renal cancer * Recent changes in antihypertensive treatment(s) in the last month, with the exception for diuretics where treatment stability of at least 3 months will be required * Patients who do not wish to participate to the study
References
Publications (0)
Data not yet available
No reference posted for this study.